Ma Xiaorong, Wang Jin, Zhang Wanggang, Cao Xingmei, Chen Yinxia, He Aili, Liu Jie, Yang Nan, Wang Jianli, Yang Yun, Xu Yan
Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi Province, China.
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi Province, China.
Eur J Haematol. 2016 Mar;96(3):260-8. doi: 10.1111/ejh.12584. Epub 2015 May 26.
To compare the safety and efficacy of porcine antilymphocyte globulin (pALG) and rabbit antithymocyte globulin (rATG) in treating severe aplastic anemia (SAA).
Seventy-seven patients with SAA that received immunosuppressive therapy between July 2004 and December 2013 at the Department of Hematology, the Second Affiliated Hospital of Xi'an Jiaotong University, were retrospectively analyzed. Forty-five patients received treatment including pALG (pALG group), and 32 patients received treatment including rATG (rATG group). Effective treatment rates between the two groups 1 yr after the treatment were compared; Kaplan-Meier 5-yr survival curve and log-rank test compared survival rates between the groups. All adverse responses were recorded.
The 1-yr overall response rate in the pALG group (83.78%) was significantly higher than that in the rATG group (66.67%, P = 0.036), and the 5-yr overall survival rate in the pALG group (82.22%) was also higher than that in the rATG group (68.75%), but the difference was not statistically significant (P = 0.32). The incidence of adverse events was similar in the two groups, and no treatment-related deaths occurred.
The efficacies, survival, and safety profiles of pALG-based treatments are similar to or even better than those of rATG-based treatments. These results may help guide the clinical use of pALG in immunosuppressive therapy for SAA.
比较猪抗淋巴细胞球蛋白（pALG）和兔抗胸腺细胞球蛋白（rATG）治疗重型再生障碍性贫血（SAA）的安全性和有效性。
回顾性分析2004年7月至2013年12月在西安交通大学第二附属医院血液科接受免疫抑制治疗的77例SAA患者。45例患者接受含pALG的治疗（pALG组），32例患者接受含rATG的治疗（rATG组）。比较两组治疗1年后的有效治疗率；采用Kaplan-Meier 5年生存曲线和对数秩检验比较两组的生存率。记录所有不良反应。
pALG组1年总有效率（83.78%）显著高于rATG组（66.67%，P = 0.036），pALG组5年总生存率（82.22%）也高于rATG组（68.75%），但差异无统计学意义（P = 0.32）。两组不良事件发生率相似，且未发生与治疗相关的死亡。
基于pALG的治疗的疗效、生存率和安全性与基于rATG的治疗相似，甚至更好。这些结果可能有助于指导pALG在SAA免疫抑制治疗中的临床应用。
